Urolithin A is a gut microbiome-derived metabolite produced from ellagitannins and ellagic acid found in pomegranates and walnuts. It stimulates mitophagy (mitochondrial recycling), improving mitochondrial health and function by clearing damaged mitochondria and promoting biogenesis. Only ~30% of people naturally produce urolithin A, making supplementation a reliable alternative.

Mechanism of Action

Mechanism of Action: Urolithin A

Microbiome-Dependent Production

Urolithin A is not found in food directly. It is produced by specific gut bacteria (Gordonibacter urolithinfaciens, Ellagibacter isourolithinifaciens) through metabolism of dietary ellagitannins and ellagic acid found in pomegranates, walnuts, and berries. Approximately 40% of individuals lack the microbial machinery to produce urolithin A endogenously, which has driven development of direct supplementation (Mitopure/Timeline).

Mitophagy Activation

Urolithin A is the first natural compound demonstrated to induce mitophagy across species (C. elegans, mice, humans). The mechanism involves stabilization of PINK1 on depolarized mitochondrial outer membranes, which recruits and activates the E3 ubiquitin ligase Parkin. Parkin ubiquitinates mitochondrial surface proteins (MFN1/2, VDAC1), which are recognized by autophagy receptors (p62, OPTN, NDP52) that bridge damaged mitochondria to autophagosomes.

Mitochondrial Quality Control Cycle

The combination of enhanced mitophagy (clearance) and compensatory biogenesis (renewal) creates a quality control cycle that replaces old, dysfunctional mitochondria with new, efficient ones. This rejuvenation of the mitochondrial network improves oxidative phosphorylation efficiency, reduces reactive oxygen species production, and enhances cellular energy capacity.

Human Clinical Evidence

Phase I/II clinical trials have demonstrated that urolithin A supplementation (500-1000 mg/day) improves mitochondrial biomarkers in skeletal muscle of middle-aged and elderly subjects. Muscle biopsies show upregulation of mitophagy genes, improved mitochondrial respiration, and increased acylcarnitine levels indicating enhanced fatty acid oxidation. Functional outcomes include improved muscle endurance and reduced inflammatory markers.

Senescence and Aging

Urolithin A has been shown to reduce cellular senescence markers (p16, p21, SA-β-gal) and suppress the senescence-associated secretory phenotype (SASP). By clearing dysfunctional mitochondria that drive senescence-associated ROS production, urolithin A addresses a root cause of cellular aging rather than merely managing symptoms.

Muscle Health

Beyond mitochondrial effects, urolithin A preserves muscle mass during aging by reducing atrophy gene expression (atrogin-1, MuRF1) and maintaining satellite cell function. In preclinical models, it improves exercise capacity and prevents age-related muscle decline, positioning it as a promising intervention for sarcopenia.

Research

Safety Profile

Safety Profile: Urolithin A

Common Side Effects

• Mild gastrointestinal symptoms: nausea, bloating, and diarrhea
• Headache
• Mild muscle soreness (possibly related to enhanced mitophagy/autophagy)
• Generally very well tolerated in clinical trials at doses up to 1000 mg/day

Serious Adverse Effects

• No serious adverse events reported in published clinical trials (Amazentis Mitopure studies)
• Long-term safety data beyond 4 months is limited
• Theoretical concern: excessive mitophagy could be detrimental in certain metabolic or mitochondrial disease states
• No confirmed organ toxicity at studied doses

Contraindications

• Known hypersensitivity to urolithin A or product excipients
• Pregnancy and lactation (insufficient safety data)
• Active mitochondrial myopathy or mitochondrial disease (effect of enhanced mitophagy unknown)
• Children (no pediatric data)

Drug Interactions

• Immunosuppressants: Autophagy modulation may affect immune function
• Mitochondria-targeted therapies: Overlapping mechanisms; effects unknown
• CYP450 interactions: Not well characterized; preliminary data suggests low interaction potential
• Pomegranate-derived supplements: Urolithin A is a natural gut metabolite of ellagic acid from pomegranate; supplementation bypasses gut conversion, avoiding variable metabolism

Population-Specific Considerations

• Aging population: Primary target demographic; clinical trials show improved mitochondrial function and muscle endurance markers
• Gut microbiome variability: Only ~40% of people naturally produce urolithin A from dietary pomegranate/ellagitannins; direct supplementation bypasses this limitation
• Athletes: Emerging interest for muscle recovery and mitochondrial health
• Novel supplement: Relatively new to market (Mitopure by Amazentis is the primary commercial form); regulatory status as dietary supplement
• GRAS status: Urolithin A has received FDA GRAS designation, supporting general safety at intended use levels

Pharmacokinetic Profile